tapebrief
AMGN · Q3 2025

AMGN · Q2 2025 Earnings

Bullish

Amgen

Reported August 5, 2025

30-second summary

Revenue grew 9% YoY to $9.18B in Q2 with non-GAAP EPS of $6.02 and non-GAAP operating margin of 48.9%, driven by 15 products delivering double-digit growth led by Rare Disease (+27.8%) and General Medicine (+12.8%). Management raised the bar on R&D spend (now growing >20% in 2025) and trimmed the full-year non-GAAP operating margin expectation to "roughly 45%" of product sales — a deliberate reinvestment trade clearly tied to Maritide's four Phase III studies and a maturing late-stage pipeline. Inflammation was the soft spot at -1.4% YoY, but the read is a portfolio firing on volume despite industry-wide net price erosion.

Headline numbers

EPS

Q2 FY2025

$6.02

Revenue

Q2 FY2025

$9.18B

+9.0% YoY

Gross margin

Q2 FY2025

65.7%

Free cash flow

Q2 FY2025

$1.91B

Operating margin

Q2 FY2025

30.3%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$9.18B+9.0%
EPS$6.02—
Gross margin65.7%—
Operating margin30.3%—
Free cash flow$1.91B—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
General Medicine$2.432B+12.8%
Rare Disease$1.525B+27.8%
Inflammation$2.362B-1.4%
Oncology$1.818B+11.0%
Established Products$0.533B-5.0%
Repatha sales$696M—
EVENITY sales$518M—
Prolia sales$1,122M—
TEZSPIRE sales$342M—
BLINCYTO sales$384M—
IMDELLTRA sales$134M—

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Product sales growth9% YoY
Non-GAAP operating margin48.9%

Management tone

Management framed the quarter notably more assertively than typical pharma cadence — the standard hedges around regulatory and competitive risk were thinner, and the spend signal was unmistakably forward-leaning.

R&D investment shifted from "elevated" to "accelerating sharply." Last guide implied R&D growth in the high-teens; this quarter management explicitly stated "we now expect non-GAAP R&D expense to grow over 20% in 2025," with Q2 already at $1.7B (+18% YoY). The corresponding cut in non-GAAP operating margin expectation to "roughly 45%" of product sales is the price of that decision, and management is not apologizing for it: "We believe the world needs more innovation, not less, and we're continuing to invest heavily in innovation to support long-term growth." This is offense, not defense.

Maritide's framing escalated from single-asset to platform. Management described it as "a promising treatment advance for people living with obesity, obesity-related conditions, and type C diabetes. With four Phase III studies underway and obstructive sleep apnea set to initiate this year, we are well-positioned to deliver a robust and comprehensive clinical knowledge base." The pre-launch infrastructure build and four-study Phase III footprint imply Amgen is operating as if approval is the planning baseline, not a probabilistic milestone.

IMDELLTRA moved from "launch in flight" to standard-of-care candidate. Management asserted "IMDELLTRA has the potential to become the new standard of care for second-line small-cell lung cancer," citing 40% reduction in mortality risk and >5-month median OS extension from DELPHI-301. With $134M in Q2 sales and >half of doses now in community settings, the durability case is being made on data, not aspiration.

Pricing rhetoric flipped from headwind to differentiator. Where industry commentary has emphasized net price erosion, Amgen reframed: "With net selling prices for medicines declining across the industry, volume growth is a key differentiator. And once again, this quarter, that's what we delivered... we expect less net price erosion than we've experienced historically." The 9% product sales growth is being explicitly attributed to portfolio breadth as a structural advantage.

Biosimilars are now treated as a growth engine, not a mature tail. The 40% YoY growth to $661M and the $12B cumulative-sales callout reposition the franchise from cash-cow afterthought to genuine top-line contributor.

Recurring themes management leaned on this quarter:

Volume growth offsetting pricing pressure across industryPortfolio breadth with 15 products delivering double-digit growthObesity franchise (Maritide, Avenity) as major growth vector with substantial TAMBispecific T-cell engager platform redefining oncology standards of careLate-stage pipeline maturation with multiple Phase III readouts expectedAI integration across value chain from discovery to commercial execution

Risks management surfaced:

Net selling price erosion across industry (though characterized as manageable)Biosimilar competition on Prolia (three launches already)Tariff impacts on business (estimated impact included in guidance, unimplemented tariffs excluded)IMDELTRA community setting adoption still building (over half doses in community, implying potential adoption friction)Regulatory execution risk on multiple late-stage programs (Maritide CV/HF, Olpaceran, APLISNA GMG, Tespire COPD/CRSwNP)

Q&A highlights

Courtney Breen · Bernstein

Why is Maritide's three-step dose escalation design with direct maintenance dose selection better than stepwise titration seen in market practice? How will physicians select the right maintenance dose with only titration feedback?

Maritide as a monoclonal antibody has smooth, steady dose escalation with progressive benefit from tolerability. The 21mg starting dose has low GI event risk. Phase 3 design carefully conceived to readout dose proportion and benefit. Long-term treatment data will guide optimal maintenance use where patients and doctors work together on doses and schedules.

21-milligram starting dose has very low risk of serious GI eventsPhase 3 studies multiple doses to provide graded understanding of dose and responseChronic obesity and weight management require long-term maintenance therapyStudies will guide optimal use for long-term maintenance with flexible dosing and scheduling

Omer Rafat · Evercore ISI

Is the PCSK9 outcomes trial (LES-CVOT) readout timing in H2 2025 driven by the 4.5-year follow-up period or by hitting predefined event thresholds of 750+ events on triple therapy and 1250 on quadruple therapy?

Readout is purely based on accumulated events and event rates, not the 4.5-year follow-up timeline. Expected readout in second half of 2025 for this primary prevention PCSK9 study on cardiovascular risk reduction.

LES-CVOT is primary prevention study of PCSK9 inhibitionReadout expected in second half of 2025Readout driven by event accumulation, not time-based milestone

Chris Schott · J.P. Morgan

What is the clinical bar for meaningful benefit from Repatha in the primary prevention PCSK9 study, and how significant a driver could positive data be for the franchise?

No specific LDL-C level confers better outcomes; suppressing LDL-C in high-risk patients without prior MI or revascularization is the opportunity. Field calibrated to what meaningful outcome looks like from secondary prevention experience. Already 40% of Repatha new-to-brand Rx from primary prevention patients. Positive data could reinforce aggressive LDL guidelines, remove payer barriers, and expand PCSK9 penetration.

40% of Repatha new-to-brand prescriptions already from primary prevention patientsNo specific LDL-C target identified as clinically optimalPotential to reinforce guidelines and remove prior authorization barriersGoal is to expand PCSK9 penetration in both secondary and primary prevention

Luca Issy · RBC Capital

What is Amgen's appetite to add an oral small molecule to obesity pipeline via BD or organic discovery? What percentage of obesity market could ultimately be oral vs. injectable?

Amgen is open to BD and actively watching for interesting innovation in obesity. Company has studied these pathways for over a decade; pipeline includes both incretin and non-incretin pathway medicines, some potentially oral. Maritide is flagship product with clear differentiation for chronic weight management with cardiometabolic and mortality benefits. Orals will constitute a decent portion of market but company excited about Maritide's persistence and chronic treatment advantages. Will share more on broader Maritide program in due course.

Only ~2% of obesity patients currently addressed by medicinesPipeline includes non-oral medicines in developmentSome pipeline medicines may be given orallyMaritide differentiation is chronic weight management with cardiometabolic outcomes

Salveen Richter · Goldman Sachs

How is Amgen thinking about Medicaid MSN and other shifting drug pricing proposals from the administration? What is the company's strategy on DTC advertising?

Too early to discuss details on specific proposals like Medicaid MSN. Management believes healthcare reform is needed and medicines should be more affordable and accessible. Amgen agrees innovation must be preserved and rewards innovation fairly. Company welcomes government focus on foreign pricing's role in protecting innovation ecosystem. Early days for specifics; expects to work with administration to advance goals. On DTC, management did not directly address.

Reform needed in U.S. healthcare systemMedicines should be more affordable and accessibleInnovation ecosystem and fair rewards for innovation must be preservedCompany has good working relationship with current administration

What to watch into next quarter

Maritide Phase 2 Part 2 readout in Q4 2025 — chronic weight management data is the most consequential single catalyst on the calendar; watch for tolerability profile at the 21mg starting dose and durability of weight loss vs. competitor benchmarks

LES-CVOT readout — event-driven trigger expected in 2H 2025; watch whether primary-prevention cardiovascular benefit is statistically and clinically meaningful enough to move LDL guidelines and reduce payer friction on Repatha

Non-GAAP operating margin trajectory in 2H — Q2 ran at 48.9% but FY guide is "roughly 45%"; the 2H R&D step-up implies a sharp sequential margin compression. Watch whether the actual 2H margin lands in line with the ~45% FY math or whether spend accelerates further

IMDELLTRA community-setting adoption — sales of $134M with >half in community settings; watch whether community share continues to build or plateaus, which will signal whether the "new standard of care" framing translates to broad uptake or remains tertiary-centric

Inflammation segment — the -1.4% YoY print is the only soft spot; watch whether TEZSPIRE growth in COPD/CRSwNP indications can flip the segment to growth in 2H, or whether continued erosion forces a guide trim

Biosimilar growth durability — 40% YoY to $661M with three Prolia biosimilars now competing; watch whether Amgen's own biosimilar growth sustains as the Prolia franchise contracts

Sources

  1. Amgen Q2 2025 earnings press release (SEC filing, dated 2025-08-05): https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm
  2. Amgen Q2 2025 earnings call prepared remarks and Q&A (referenced via extracted transcript content)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.